Replies to post #3447 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

That's correct--no one knows. But so long as the difference is only seen after death, and otherwise has no histological, toxicological, behavioral effects in living tissue/animals--even the FDA is going to have a hard time justifying preventing another clinical trial. Though I have cited a personal belief that there is a 30% chance that they could do so in spite of the illogic.

Caveat: the electron microscopy study is the last step to establishing the lack of even submicroscopic effects in living--then 'flash-frozen--tissue.

NeuroInvestment

[Aiming4]

Gfp - my question in #msg-16569691 was referring to the situation that I would guess exists, i.e. everyone and their brother knows the details of which organ was involved, what the histo abnormality was, etc... *except* us - i.e. the small investors.

I don't think it's realistic to believe that Cortex's competitors don't already know all of the details involved in Cortex's CX-717 problems with the FDA, that's what I was curious in getting a response on.

Maybe that info can realistically be kept confidential, but it seems unlikely to me.

Which makes it all the more frustrating that small investors are the only ones that don't know info that might help in investing decisions, e.g. which organ is involved, what the dosing limitations are, etc... Aiming4.